Test Bank for Pharmacotherapeutics for Advanced Practice: A Practical Approach 5th Edition

TEST BANK 7



Pharmacotherapeutics for Advanced Practice: A Practical Approach
7 7 7 7 7 7




by Virginia Poole Arcangelo, Andrew M. Peterson
7 7 7 7 7 7


Fifth Edition
7




FULL TEST BANK!!!
7 7

,Chapter 1 Issues for the Practitioner in Drug Therapy
7 7 7 7 7 7 7 7




MULTIPLE7CHOICE

1. Nurse7practitioner7prescriptive7authority7is7regulated7by:
A. The7National7Council7of7State7Boards7of7Nursing
B. The7U.S.7Drug7Enforcement7Administration
C. The7State7Board7of7Nursing7for7each7state
D. The7State7Board7of7Pharmacy

ANS:7 C PTS:7 1

2. Physician7Assistant7(PA)7prescriptive7authority7is7regulated7by:
A. The7National7Council7of7State7Boards7of7Nursing
B. The7U.S.7Drug7Enforcement7Administration
C. The7State7Board7of7Nursing
D. The7State7Board7of7Medical7Examiners

ANS:7 D PTS:7 1

3. Clinical7judgment7in7prescribing7includes:
A. Factoring7in7the7cost7to7the7patient7of7the7medication7prescribed
B. Always7prescribing7the7newest7medication7available7for7the7disease7process
C. Handing7out7drug7samples7to7poor7patients
D. Prescribing7all7generic7medications7to7cut7costs

ANS:7 A PTS:7 1

4. Criteria7for7choosing7an7effective7drug7for7a7disorder7include:
A. Asking7the7patient7what7drug7they7think7would7work7best7for7them
B. Consulting7nationally7recognized7guidelines7for7disease7management
C. Prescribing7medications7that7are7available7as7samples7before7writing7a7prescription
D. Following7U.S.7Drug7Enforcement7Administration7(DEA)7guidelines7for7
prescribing
ANS:7 B PTS:7 1

5. Nurse7practitioner7practice7may7thrive7under7health-care7reform7due7to:
A. The7demonstrated7ability7of7nurse7practitioners7to7control7costs7and7improve7patient7
outcomes
B. The7fact7that7nurse7practitioners7will7be7able7to7practice7independently
C. The7fact7that7nurse7practitioners7will7have7full7reimbursement7under7health-
care7reform
D. The7ability7to7shift7accountability7for7Medicaid7to7the7state7level
ANS:7 A PTS:7 1

, lOM oA R

007 614
7 7
cP S D| 21




Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
7 7 7 7 7 7




MULTIPLE7CHOICE

1. A7patient's7nutritional7intake7and7lab7work7reflects7hypoalbuminemia.7This7is7critical7to7p
rescribing7because:
A. Distribution7of7drugs7to7target7tissue7may7be7affected
B. The7solubility7of7the7drug7will7not7match7the7site7of7absorption
C. There7will7be7less7free7drug7available7to7generate7an7effect
D. Drugs7bound7to7albumin7are7readily7excreted7by7the7kidney
ANS:7 A PTS:7 1

2. Drugs7that7have7a7significant7first-pass7effect:
A. Must7be7given7by7the7enteral7(oral)7route7only
B. Bypass7the7hepatic7circulation
C. Are7rapidly7metabolized7by7the7liver7and7may7have7little7if7any7desired7action
D. Are7converted7by7the7liver7to7more7active7and7fat-soluble7forms
ANS:7 C PTS:7 1

3. The7route7of7excretion7of7a7volatile7drug7will7likely7be:
A. The7kidneys
B. The7lungs
C. The7bile7and7feces
D. The7skin
ANS:7 B PTS:7 1

4. Medroxyprogesterone7(Depo7Provera)7is7prescribed7IM7to7create7a7storage7reservoir7of7the7d
rug.7Storage7reservoirs:
A. Assure7that7the7drug7will7reach7its7intended7target7tissue
B. Are7the7reason7for7giving7loading7doses
C. Increase7the7length7of7time7a7drug7is7available7and7active
D. Are7most7common7in7collagen7tissues
ANS:7 C PTS:7 1

5. The7NP7chooses7to7give7cephalexin7every787hours7based7on7knowledge7of7the7drug's:
A. Propensity7to7go7to7the7target7receptor
B. Biological7half-life
C. Pharmacodynamics
D. Safety7and7side7effects

ANS:7 B PTS:7 1

6. Azithromycin7dosing7requires7the7first7day's7dose7be7twice7those7of7the7other747days7of7the7p
rescription.7This7is7considered7a7loading7dose.7A7loading7dose:
A. Rapidly7achieves7drug7levels7in7the7therapeutic7range
B. Requires7four7to7five7half-lives7to7attain
C. Is7influenced7by7renal7function

, lOM oA R

007 614
7 7
cP S D| 21




D. Is7directly7related7to7the7drug7circulating7to7the7target7tissues
ANS:7 A PTS:7 1

7. The7point7in7time7on7the7drug7concentration7curve7that7indicates7the7first7sign7of7a7therapeutic7e
ffect7is7the:
A. Minimum7adverse7effect7level
B. Peak7of7action
C. Onset7of7action
D. Therapeutic7range
ANS:7 C PTS:7 1

8. Phenytoin7requires7a7trough7level7be7drawn.7Peak7and7trough7levels7are7done:
A. When7the7drug7has7a7wide7therapeutic7range
B. When7the7drug7will7be7administered7for7a7short7time7only
C. When7there7is7a7high7correlation7between7the7dose7and7saturation7of7receptor7sites
D. To7determine7if7a7drug7is7in7the7therapeutic7range
ANS:7 D PTS:7 1

9. A7laboratory7result7indicates7the7peak7level7for7a7drug7is7above7the7minimum7toxic7c
oncentration.7This7means7that7the:
A. Concentration7will7produce7therapeutic7effects
B. Concentration7will7produce7an7adverse7response
C. Time7between7doses7must7be7shortened
D. Duration7of7action7of7the7drug7is7too7long
ANS:7 B PTS:7 1

10. Drugs7that7are7receptor7agonists7may7demonstrate7what7property?
A. Irreversible7binding7to7the7drug7receptor7site
B. Up-regulation7with7chronic7use
C. Desensitization7or7down-regulation7with7continuous7use
D. Inverse7relationship7between7drug7concentration7and7drug7action
ANS:7 C PTS:7 1

11. Drugs7that7are7receptor7antagonists,7such7as7beta7blockers,7may7cause:
A. Down-regulation7of7the7drug7receptor
B. An7exaggerated7response7if7abruptly7discontinued
C. Partial7blockade7of7the7effects7of7agonist7drugs
D. An7exaggerated7response7to7competitive7drug7agonists
ANS:7 B PTS:7 1

12. Factors7that7affect7gastric7drug7absorption7include:
A. Liver7enzyme7activity
B. Protein-binding7properties7of7the7drug7molecule
C. Lipid7solubility7of7the7drug
D. Ability7to7chew7and7swallow

ANS:7 C PTS:7 1




WWW.TEGTBANKTANK.COM